结直肠癌组织中错配修复蛋白基因表达与临床病理及KRAS BRAF基因突变的相关性分析  

Correlation of expression of mismatch repair proteins and KRAS/BRAF mutations with clinicopathologi-cal parameters in colorectal carcinoma

作　　者：高菲 郭业兵 王木森 Gao Fei;Guo Yebing;Wang Musen(Department of Pathology,Dong E County People′s Hospital of Shangdong Province,Shangdong 252200,China)

机构地区：[1]山东省东阿县人民医院病理科,252200

出　　处：《实用医技杂志》2022年第5期475-479,共5页Journal of Practical Medical Techniques

摘　　要：目的分析结直肠癌肿瘤组织中错配修复蛋白(MMR)表达与临床病理因素及KRAS、BRAF基因突变的相关性。方法采用免疫组织化学法和扩增阻滞突变系统对212例结直肠癌根治标本石蜡组织的MMR蛋白表达及KRAS、BRAF基因突变状态进行回顾性分析。结果212例结直肠癌肿瘤组织中错配修复蛋白表达缺失率为11.3%(24/212)。212例结直肠癌组织中KRAS、BRAF基因的突变率分别为40.6%(86/212)、3.3%(7/212)。结论错配修复蛋白联合KRAS、BRAF突变检测可为结直肠癌患者预后评估及个体化治疗提供依据。Objective To investigate the association of mismatch repair(MMR)protein expression and KRAS/BRAF mutations with clinicopathological characteristics of colorectal carcinoma(CRC).Methods A total of 212 cases of CRC were analysed for the expression of MMR proteins,determined using immunohistochemistry,and the KRAS/BRAF gene mutations,determined using amplification refractory mutation system.Results Out of 212,24 cases(11.3%)reported loss of expression of at least one MMR protein.Mutations of KRAS and BRAF genes were observed in 86(40.6%)and 7(3.3%)cases,respectively.Conclusion Determination of KRAS/BRAF gene mutations and the status of MMR protein expression may aid individualized treatment and facilitate prognosis evaluation for patients with CRC.

关 键 词：结直肠肿瘤 免疫组织化学 错配修复蛋白 KRAS BRAF 

分 类 号：R735.34[医药卫生—肿瘤]